Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
Public ClinicalTrials.gov record NCT00219635. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Assessment of efficacy and safety UK-390,957
Study identification
- NCT ID
- NCT00219635
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2005 (Type not available)
- Primary completion
- Jul 2005 (Actual)
- Completion
- Jul 2005 (Actual)
- Last update posted
- Nov 7, 2012
2005
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | — | — |
| Pfizer Investigational Site | San Bernardino | California | — | — |
| Pfizer Investigational Site | Metairie | Louisiana | — | — |
| Pfizer Investigational Site | Watertown | Massachusetts | — | — |
| Pfizer Investigational Site | Kansas City | Missouri | — | — |
| Pfizer Investigational Site | Washington | Missouri | — | — |
| Pfizer Investigational Site | New York | New York | — | — |
| Pfizer Investigational Site | Williamsville | New York | — | — |
| Pfizer Investigational Site | Beachwood | Ohio | — | — |
| Pfizer Investigational Site | Portland | Oregon | — | — |
| Pfizer Investigational Site | Knoxville | Tennessee | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | Houston | Texas | — | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00219635, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00219635 live on ClinicalTrials.gov.